1. Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice
- Author
-
Takashi Kitani, Noriyuki Yamashita, Noriko Watanabe-Uehara, Tomoharu Ida, Benjamin D. Humphreys, Kunihiro Nakai, Yuhei Kirita, Tetsuro Kusaba, Keiichi Tamagaki, Tomohiro Nakata, Kisho Ikeda, Aya Tomita, Satoaki Matoba, and Masahiro Uehara
- Subjects
0301 basic medicine ,DNA Repair ,DNA damage ,DNA repair ,Morpholines ,lcsh:Medicine ,Antineoplastic Agents ,Apoptosis ,Ataxia Telangiectasia Mutated Proteins ,medicine.disease_cause ,Article ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Renal fibrosis ,Fanconi anemia ,medicine ,Animals ,Phosphorylation ,lcsh:Science ,Cisplatin ,Kidney ,Mutation ,Multidisciplinary ,business.industry ,lcsh:R ,Acute kidney injury ,Cell Cycle Checkpoints ,Acute Kidney Injury ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Pyrones ,030220 oncology & carcinogenesis ,Cancer research ,lcsh:Q ,Mutant Proteins ,Tumor Suppressor Protein p53 ,business ,Signal Transduction ,medicine.drug - Abstract
The DNA damage response after kidney injury induces cell cycle arrest in renal tubular epithelial cells, resulting in the secretion of pro-fibrotic cytokines, thereby promoting interstitial fibrosis in a paracrine manner. Phosphorylation of ataxia-telangiectasia mutated (ATM) is the initial step in the DNA damage response and subsequent cell cycle arrest; however, the effects of ATM inhibition on the injured kidney have not been explored. Pharmacological ATM inhibition by KU55933 in cisplatin-treated mice did not ameliorate, but instead exacerbated cisplatin-induced DNA damage and tubular injury, thereby increasing mortality. Analysis of isolated tubular epithelia by FACS from bigenic SLC34a1-CreERt2; R26tdTomato proximal tubular-specific reporter mice revealed that KU55933 upregulated p53 and subsequent pro-apoptotic signaling in tubular epithelia of cisplatin-treated mice, leading to marked mitochondrial injury and apoptosis. In addition, KU55933 attenuated several DNA repair processes after cisplatin treatment, including single-strand DNA repair and Fanconi anemia pathways, suggesting that DNA repair after dual treatment of cisplatin and KU55933 was not sufficient to prevent the cisplatin-induced tubular injury. Our study suggested that ATM inhibition does not increase DNA repair after cisplatin-induced DNA damage and exacerbates tubular injury through the upregulation of p53-dependent pro-apoptotic signaling. Acute kidney injury must be carefully monitored when ATM inhibitors become available in clinical practice in the future.
- Published
- 2020
- Full Text
- View/download PDF